Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

John King

Pulmonary Disease Macon, GA Medical Doctor

NPI 1669465860 CMS profile 165816

250 Martin Luther King Jr Blvd, Macon, GA 31201

Open in the dashboard

General payments

$19,277

65 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, John King of Macon, GA is reported in the CMS Open Payments database as having received $19,277 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $236 13
2021 General $1,212 19
2020 General $5,440 13
2019 General $12,388 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John King
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to John King were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year John King Pulmonary Disease median Middle half National median
2019 $12,388 $377 $109–$1,340 $163
2020 $5,440 $230 $56–$907 $114
2021 $1,212 $269 $68–$1,072 $132
2022 $236 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Insmed, Inc. $18,563 31 payments
  2. GlaxoSmithKline, LLC. $173 11 payments
  3. Actelion Pharmaceuticals US, Inc. $162 9 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $149 1 payment
  5. AstraZeneca Pharmaceuticals LP $130 8 payments
  6. United Therapeutics Corporation $66 3 payments
  7. Melinta Therapeutics, Inc. $18 1 payment
  8. Merck Sharp & Dohme Corporation $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,985 7 payments
  2. Consulting Fee $2,700 3 payments
  3. Food and Beverage $1,363 47 payments
  4. Travel and Lodging $890 4 payments
  5. Education $339 4 payments
Products named General payments · program years 2019–2022
  1. Arikayce $16,193 24 payments
  2. OPSUMIT $162 9 payments
  3. SPIRIVA RESPIMAT $149 1 payment
  4. NUCALA $122 8 payments
  5. UPTRAVI $75 4 payments
  6. BREZTRI $66 4 payments
  7. SYMBICORT $64 4 payments
  8. TRELEGY ELLIPTA $51 3 payments
  9. TYVASO $45 2 payments
  10. Orbactiv $18 1 payment
  11. Other $50 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record